About us
Who are we, and why are we passionate about pigs? At Sus Clinicals, our mission is to help accelerate the development of breakthrough therapeutics. We believe faster, more efficient pre-clinical testing is the key to getting life-saving treatments to patients sooner. Using a “pig as a platform” approach, we can generate tumors and other diseases on demand in our Oncopig®, then perform customized testing with our client’s medical device, drug, or diagnostic to give them the predictive data they need to move these therapies to the clinic faster.
Our story
Oncopig Cancer Model®
2024
- Successful induction of glioma
2023
- Expansion of models with successful inductions in lung, colon, bladder
2022
- Successful inductions in kidney
2021
- Patent application filed for targeted patch-based tumor induction technology
2020
- Sus Clinicals licenses first inducible large animal cancer model (Oncopig®) from University of Illinois
- Patent application filed for “Modeling Oncology on Demand”
- Model validated via liver tumor inductions
Regulatory Recognition
2024
- FDA clears streamlined process for shipping Oncopigs to research sites
2023
- FDA Center for Veterinary Medicine recognizes Oncopig production sites
2022
- Sus Clinicals receives FDA clearance for transgenic Oncopig
Biomedical Models
2023
- Sus Clinicals licenses breakthrough cell line technology to advance large animal preclinical research capabilities
- Sus Clinicals licenses new Oncopig hybrid with increased capability for comorbidities
- National Cancer Institute awards Sus Clinicals $2 million SBIR Phase II grant for drug targeting and liquid biopsy
2022
- First demonstration of comorbidity via imaging
Meet our leadership team
Jeffrey D. Weedman
Executive Chair & Co-Founder
Dr. Jessicca M. Rege
Chief Executive Officer
Dr. Larry Schook
Chief Scientific Officer & Co-Founder
Stephen J. Baggott
Chief Operating Officer
Geoffrey T. Marshall
Chief Financial Officer
Dr. Kyle M. Schachtschneider
VP of R&D and Services
Get in touch
"*" indicates required fields
Locations
Sus Clinicals scientific headquarters is in Chicago, IL. We have two full labs in Chicago, supporting work for clients and internal R&D. We also have lab facilities in Urbana, IL. Our commercial operations are located in Cincinnati, OH.
Ethics and governance
Sus Clinicals always strives to adhere to the highest standards of ethical behavior in all we do. We and our research partners comply with all applicable laws and regulations, including standards for the use of biomedical research animals. These include best practices as set forth by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and the American Association for Laboratory Animal Science (AALAS). We conduct our research with robust team training, comprehensive quality assurance and integrated data management practices. We are also committed to transparency, including disclosing any conflicts of interest that may arise in the course of our work. As part of this, we ensure compliance with requirements under any government-funded or other sponsored research, which includes having a clearly defined Financial Conflict of Interest in Research (FCOIR) policy (Click here to view PDF)
